---
title: "Glaukos completes enrollment in Phase 2 trial of GLK-321 for Demodex blepharitis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290819532.md"
description: "Glaukos Corporation has completed patient enrollment in a Phase 2 clinical trial for GLK-321, an investigational eyelid-applied treatment for Demodex blepharitis. The study aims to evaluate the drug's ability to clear key disease signs over six weeks. This trial supports the development of a new ocular-surface franchise utilizing the iLution drug-delivery platform, targeting a large, underdiagnosed market. Clinical results have not yet been presented."
datetime: "2026-06-25T11:00:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290819532.md)
  - [en](https://longbridge.com/en/news/290819532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290819532.md)
---

# Glaukos completes enrollment in Phase 2 trial of GLK-321 for Demodex blepharitis

-   Glaukos completed patient enrollment in a Phase 2 trial of GLK-321 for Demodex blepharitis; results have not yet been presented. \* The study will assess whether the investigational eyelid-applied treatment can clear a key sign of the disease over six weeks. \* The trial is designed to support a potential new ocular-surface franchise using the iLution drug-delivery platform, targeting a large, underdiagnosed market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260625276927) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)

## Related News & Research

- [Glaukos completes enrollment in 510(k) pivotal study of PRESERFLO MicroShunt for advanced glaucoma patients](https://longbridge.com/en/news/293920684.md)
- [Glaukos CFO Alex R. Thurman disposes of USD 1.6 million in common shares](https://longbridge.com/en/news/293383036.md)
- [Bank of New York Mellon Corp Sells 12,667 Shares of Glaukos Corporation $GKOS](https://longbridge.com/en/news/293838194.md)
- [Health Rounds: Experimental GLP-1 drug improves fatty livers independent of weight loss in mid-stage trial](https://longbridge.com/en/news/293661908.md)
- [UBS Group Begins Coverage on Glaukos (NYSE:GKOS)](https://longbridge.com/en/news/294063117.md)